001     823869
005     20210129224857.0
024 7 _ |a 10.1002/cbic.201500623
|2 doi
024 7 _ |a 1439-4227
|2 ISSN
024 7 _ |a 1439-7633
|2 ISSN
024 7 _ |a WOS:000375124500003
|2 WOS
024 7 _ |a altmetric:5973924
|2 altmetric
024 7 _ |a pmid:26910367
|2 pmid
037 _ _ |a FZJ-2016-06509
082 _ _ |a 540
100 1 _ |a Nagel-Steger, Luitgard
|0 P:(DE-Juel1)162443
|b 0
|u fzj
245 _ _ |a An Account of Amyloid Oligomers: Facts and Figures Obtained from Experiments and Simulations
260 _ _ |a Weinheim
|c 2016
|b Wiley-VCH
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1479800458_4739
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The deposition of amyloid in brain tissue in the context of neurodegenerative diseases involves the formation of intermediate species—termed oligomers—of lower molecular mass and with structures that deviate from those of mature amyloid fibrils. Because these oligomers are thought to be primarily responsible for the subsequent disease pathogenesis, the elucidation of their structure is of enormous interest. Nevertheless, because of the high aggregation propensity and the polydispersity of oligomeric species formed by the proteins or peptides in question, the preparation of appropriate samples for high-resolution structural methods has proven to be rather difficult. This is why theoretical approaches have been of particular importance in gaining insights into possible oligomeric structures for some time. Only recently has it been possible to achieve some progress with regard to the experimentally based structural characterization of defined oligomeric species. Here we discuss how theory and experiment are used to determine oligomer structures and what can be done to improve the integration of the two disciplines.
536 _ _ |a 553 - Physical Basis of Diseases (POF3-553)
|0 G:(DE-HGF)POF3-553
|c POF3-553
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Owen, Michael C.
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Strodel, Birgit
|0 0000-0002-8734-7765
|b 2
|e Corresponding author
773 _ _ |a 10.1002/cbic.201500623
|g Vol. 17, no. 8, p. 657 - 676
|0 PERI:(DE-600)2020469-3
|n 8
|p 657 - 676
|t ChemBioChem
|v 17
|y 2016
|x 1439-4227
856 4 _ |y Restricted
|u https://juser.fz-juelich.de/record/823869/files/An%20Account%20of%20Amyloid%20Oligomers%3A%20Facts%20and%20Figures%20Obtained%20from%20Experiments%20and%20Simulations_2016.pdf
856 4 _ |y Restricted
|x icon
|u https://juser.fz-juelich.de/record/823869/files/An%20Account%20of%20Amyloid%20Oligomers%3A%20Facts%20and%20Figures%20Obtained%20from%20Experiments%20and%20Simulations_2016.gif?subformat=icon
856 4 _ |y Restricted
|x icon-1440
|u https://juser.fz-juelich.de/record/823869/files/An%20Account%20of%20Amyloid%20Oligomers%3A%20Facts%20and%20Figures%20Obtained%20from%20Experiments%20and%20Simulations_2016.jpg?subformat=icon-1440
856 4 _ |y Restricted
|x icon-180
|u https://juser.fz-juelich.de/record/823869/files/An%20Account%20of%20Amyloid%20Oligomers%3A%20Facts%20and%20Figures%20Obtained%20from%20Experiments%20and%20Simulations_2016.jpg?subformat=icon-180
856 4 _ |y Restricted
|x icon-640
|u https://juser.fz-juelich.de/record/823869/files/An%20Account%20of%20Amyloid%20Oligomers%3A%20Facts%20and%20Figures%20Obtained%20from%20Experiments%20and%20Simulations_2016.jpg?subformat=icon-640
856 4 _ |y Restricted
|x pdfa
|u https://juser.fz-juelich.de/record/823869/files/An%20Account%20of%20Amyloid%20Oligomers%3A%20Facts%20and%20Figures%20Obtained%20from%20Experiments%20and%20Simulations_2016.pdf?subformat=pdfa
909 C O |o oai:juser.fz-juelich.de:823869
|p VDB
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)162443
913 1 _ |a DE-HGF
|b Key Technologies
|l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences
|1 G:(DE-HGF)POF3-550
|0 G:(DE-HGF)POF3-553
|2 G:(DE-HGF)POF3-500
|v Physical Basis of Diseases
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2016
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CHEMBIOCHEM : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a No Authors Fulltext
|0 StatID:(DE-HGF)0550
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)ICS-6-20110106
|k ICS-6
|l Strukturbiochemie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)ICS-6-20110106
981 _ _ |a I:(DE-Juel1)IBI-7-20200312


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21